CCR5 and metabolic dysfunction-associated steatohepatitis: Cenicriviroc (CVC) is a CCR2/CCR5 inhibitor that inhibits macrophage accumulation and improves fibrosis in animal models of NASH.69 In a phase‐IIb randomized, placebo‐controlled trial (CENTAUR), patients with NASH were randomized to CVC 150 mg QD or placebo.50 At year 1, 20% of NASH patients on CVC had ≥1 stage fibrosis improvement compared to 10% in placebo (P = .02).